Latest Capital Raises News

Avira Resources has secured a binding agreement to acquire the high-grade Mt Cattlin Gold Project and raised $2.5 million in firm commitments, positioning itself for significant exploration activity in Western Australia and Sweden.

Kairos Minerals has completed a $27 million placement and secured a landmark mineral rights agreement with Pilbara Minerals, significantly expanding its Mt York Gold Project drilling program and advancing exploration at Roe Hills.

Alexium International Group reported a 26% rise in Q1 FY26 sales driven by new business wins and expanded foam bedding applications, while navigating tighter funding conditions.

Jade Gas Holdings has achieved continuous gas flow from two production wells and secured its first LNG sales agreement with Mongolia’s largest natural gas importer, UB Metan LLC. The company also raised $5 million to support its commercial operations.

ABx Group Limited reports strong progress in rare earth extraction and clean chemical production, backed by strategic investments and a recent $3 million capital raise.

Victory Metals has significantly upgraded its North Stanmore rare earths resource, reporting record dysprosium grades and producing a high-purity rare earth oxide. The company also secured strategic partnerships and $11.5 million in new funding.

Elevate Uranium has raised $25 million through a well-supported placement, boosting its cash reserves to nearly $44 million. The funds will accelerate its proprietary U-pgrade™ pilot plant and expand uranium resource drilling in Namibia and Australia.

TG Metals Limited reports strong progress in its September quarter with successful stockpile metallurgy, high-grade laterite discovery at Van Uden, and expanded soil geochemistry targets at both Van Uden and Gold City projects.

Artrya Limited has completed the second tranche of its share placement, raising $14.7 million to advance its AI-powered Salix platform for coronary artery disease detection.

Golden Horse Minerals has raised A$35 million through a strongly supported placement to accelerate exploration and development at its Southern Cross Gold Project in Western Australia.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Codeifai Limited reports a 10% revenue increase in Q3 2025 and completes due diligence on the QuantumAI Secure platform acquisition, signaling a strategic pivot into quantum-resilient fintech solutions.